Co-Authors
This is a "connection" page, showing publications co-authored by Van Hoang and Jean-Christophe Lagier.
Connection Strength
0.746
-
SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence. J Clin Med. 2021 Jun 15; 10(12).
Score: 0.059
-
Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France. Clin Microbiol Infect. 2021 Oct; 27(10):1516.e1-1516.e6.
Score: 0.059
-
Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clin Microbiol Infect. 2021 Jun; 27(6):931-932.
Score: 0.058
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. Int J Antimicrob Agents. 2021 Jan; 57(1):106243.
Score: 0.058
-
Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load. Int J Antimicrob Agents. 2021 01; 57(1):106244.
Score: 0.058
-
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. Int J Antimicrob Agents. 2021 01; 57(1):106237.
Score: 0.058
-
Response to advances statistical methods and designs for clinical trials for COVID-19. Int J Antimicrob Agents. 2021 01; 57(1):106235.
Score: 0.058
-
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. Int J Antimicrob Agents. 2021 Jan; 57(1):106239.
Score: 0.058
-
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. Int J Antimicrob Agents. 2021 01; 57(1):106241.
Score: 0.058
-
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19. Int J Antimicrob Agents. 2021 Jan; 57(1):106242.
Score: 0.058
-
Coinfections with SARS-CoV-2 and other respiratory viruses in Southeastern France: A matter of sampling time. J Med Virol. 2021 04; 93(4):1878-1881.
Score: 0.057
-
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar - Apr; 34:101663.
Score: 0.055
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul; 56(1):105949.
Score: 0.055